Taking propranolol with Mounjaro: what the evidence says

What the pharmacology tells us about propranolol alongside tirzepatide

Tirzepatide's pharmacokinetics have been characterised thoroughly across the SURMOUNT trial programme, which involved thousands of adults over periods of up to 72 weeks. The British National Formulary entry for tirzepatide does not list propranolol as a contraindication or a flagged interaction. Propranolol, a non-selective beta-blocker, is metabolised primarily in the liver via CYP enzymes; tirzepatide is a subcutaneously delivered peptide that does not share that hepatic metabolism route. For formal pharmacokinetic interaction purposes, there is no clinically documented collision between the two.

The more practical consideration lies in physiology rather than pharmacology. Propranolol is prescribed for a wide range of reasons, hypertension, angina, arrhythmias, anxiety, migraine prophylaxis, tremor. Each of those conditions may itself be relevant to a weight-management consultation. Tirzepatide consistently produced reductions in blood pressure alongside weight loss in its clinical trials; if you are already on propranolol partly for blood-pressure control, your prescriber will want to monitor whether combined therapy needs adjustment over time. That conversation is part of good clinical care, not a barrier to treatment for most people.

If you are wondering about a similar assessment for another heart-rate-lowering medicine, our page on taking Mounjaro with bisoprolol covers the selective beta-blocker picture in the same detail.

The gastric-emptying question and what it means for oral propranolol

One effect of tirzepatide that is worth understanding is delayed gastric emptying. This is part of how the medicine helps with appetite, but it also means that oral medicines taken at the same time may be absorbed more slowly than usual, or in a different pattern. The NHS tirzepatide medicines page notes this as a general consideration for patients on oral medicines.

Propranolol is almost always taken orally, and it does have some food- and gastric-content dependency in its absorption. Standard-release propranolol is absorbed relatively quickly; modified-release capsules have their own kinetics. In practice, the clinical significance of tirzepatide's gastric-emptying effect on propranolol absorption is not firmly established from head-to-head data, but it is a reason to mention propranolol specifically when completing your consultation, not to hide it in the medicines list.

This also applies more broadly. If you take lansoprazole or other oral medicines alongside your beta-blocker, our page on lansoprazole and Mounjaro walks through the gastric-emptying consideration in that context too.

Who this combination is most relevant for, and what the prescriber will look at

Propranolol is prescribed to a large number of people in the UK, many of whom also have a BMI that makes them eligible for tirzepatide under its licensed indication: adults with a BMI of 30 or above, or 27 or above alongside a weight-related health condition such as hypertension or cardiovascular disease. If propranolol has been prescribed for hypertension or a heart condition, that same condition may actually support eligibility rather than complicate it. You can read more about the eligibility picture on our Mounjaro BMI and eligibility page.

A prescriber reviewing your case will look at: the reason propranolol was prescribed, your current dose and formulation, your current blood pressure and heart rate, and any other medicines or health conditions that intersect with either drug. Beta-blockers can blunt the normal adrenaline-driven warning signs of hypoglycaemia; while tirzepatide's risk of causing low blood sugar without diabetes is very low, this is still a relevant background consideration if you have type 2 diabetes alongside your other conditions.

If kidney disease is part of your health history as well, our page covering Mounjaro and chronic kidney disease adds further context on how prescribers approach that combination. For a broader overview of what the consultation process involves, our guide to who can take Mounjaro is a useful starting point.

Starting Mounjaro: what the process looks like and where cost fits in

If your prescriber determines that tirzepatide is appropriate alongside propranolol, the practical experience is straightforward. Treatment arrives via DPD the next working day in plain, unbranded packaging, the pen itself is small, pre-filled and colour-coded by dose, with a dial-back needle designed to make self-injection as low-key as possible for first-timers. The starter dose of 2.5mg is chosen specifically to let your body adjust before any therapeutic increase, which matters particularly when cardiovascular co-prescribing is part of the picture.

For many people, cost is a real part of the decision. Our page on Mounjaro costs in the UK sets out what private treatment typically includes and what the price differences between providers actually reflect, so you can make a genuinely informed comparison rather than going on headline figures alone. The short version: a single transparent price covering your consultation, prescription, delivery and aftercare is a different thing from a headline pen price that adds those on separately.

Our full Mounjaro information hub covers the medicine's mechanism, evidence and what to expect from treatment week by week. And if you have further questions before booking, the nume FAQs page addresses the queries our prescribers hear most often. When you are ready to take the next step, you can start your free consultation and a GPhC-registered prescriber will review your full medicines list, including propranolol, the same day.